Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 1.13B 1B 947M 858M 1.61B 109B 1.62B 11.34B 4.37B 55.62B 4.26B 4.17B 179B P/E 2026 *
12.3x
P/E 2027 * 10.1x
Enterprise Value 1.44B 1.27B 1.2B 1.09B 2.04B 138B 2.06B 14.37B 5.54B 70.49B 5.4B 5.28B 226B EV / Sales 2026 *
1.92x
EV / Sales 2027 * 1.68x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day-2.59%
1 week+8.99%
Current month+18.42%
1 month+21.22%
3 months+22.50%
6 months+40.35%
Current year-0.37%
1 week 24.2
Extreme 24.2
27.8
1 month 21.52
Extreme 21.52
27.8
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
29.52
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Director/Board Member 69 01/02/2003
Director/Board Member 58 04/08/2022
Director/Board Member 66 01/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Sell

Chief Financial Officer

-4,139 0.0097%
16/9/26 Exercice

Chief Technology Officer

30,000 0.0705%
2/9/26 Sell

Chief Technology Officer

-3,187 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%+8.99%-0.63%-43.59% 1.17B
-0.01%+1.69%+63.50%+117.58% 1,056B
-1.61%-0.71%+48.89%+70.56% 655B
-1.12%-0.45%+19.35%+72.93% 471B
-1.72%-4.25%+37.79%+39.89% 342B
-0.40%+4.12%+22.89%+29.04% 277B
-0.51%-1.05%+12.98%+12.92% 257B
+1.32%+7.75%+55.19%+56.43% 226B
-0.61%+0.48%+34.95%+100.58% 189B
-0.24%-3.21%-27.79%-61.37% 170B
Average -0.75%+1.15%+26.71%+39.50% 364.41B
Weighted average by Cap. -0.63%+0.76%+39.84%+68.89%

Financials

2026 *2027 *
Net sales 748M 660M 624M 565M 1.06B 71.76B 1.07B 7.47B 2.88B 36.65B 2.81B 2.75B 118B 784M 692M 655M 593M 1.11B 75.28B 1.12B 7.84B 3.02B 38.44B 2.95B 2.88B 123B
Net income 99.32M 87.6M 82.87M 75.1M 141M 9.53B 142M 992M 382M 4.87B 373M 365M 15.63B 115M 102M 96.31M 87.27M 164M 11.08B 165M 1.15B 444M 5.66B 433M 424M 18.17B
Net Debt 303M 268M 253M 229M 431M 29.12B 434M 3.03B 1.17B 14.87B 1.14B 1.11B 47.76B 184M 162M 154M 139M 261M 17.67B 264M 1.84B 709M 9.02B 691M 676M 28.98B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
29/09/26 US$26.68 -2.59% 626,940
28/09/26 US$27.39 +4.82% 751,801
25/09/26 US$26.13 -0.53% 376,921
24/09/26 US$26.27 +5.25% 572,080
23/09/26 US$24.96 +2.63% 508,095
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
26.68USD
Average target price
22.50USD
Spread / Average Target
-15.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock